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DiagnosisPerinatal brain injury at term is common and often manifests with neonatal encephalopathy including
seizures. The most common aetiologies are hypoxic–ischaemic encephalopathy, intracranial haemorrhage and
neonatal stroke. Besides clinical and biochemical assessment the diagnostic evaluation rely mostly on EEG and
neuroimaging including cranial ultrasound and magnetic resonance imaging. The mechanisms underlying hyp-
oxic–ischaemic brain injury are only partly understood but include excitotoxicity, mitochondrial perturbation,
necrosis/apoptosis and inﬂammation. Neuroprotective treatment of newborns suffering fromhypoxic–ischaemic
encephalopathy with hypothermia has proven effective and has been introduced as a clinical routine. Ongoing
studies are exploring various add-on therapies including erythropoietin, xenon, topiramate, melatonin and
stem cells.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Perinatal brain injury in the term infant is common in both devel-
oped and underprivileged countries. Almost all forms of perinatal
brain injury will result into neonatal encephalopathy of which seizures
and reduced reactivity are the most frequent clinical ﬁndings.
Neonatal encephalopathy occurs in 1–3 per 1000 infants born at
term and is most commonly due to hypoxia–ischaemia (Glass et al.,
2009; Ronen et al., 1999; Vasudevan and Levene, 2013). Risk factors
for hypoxic–ischaemic encephalopathy include a gestational age above
41 weeks, prolonged membrane rupture, abnormal cardiotocography,
thick meconium, sentinel event, shoulder dystocia, tight nuchal cord,
failed vacuum (Martinez-Biarge et al., 2013), and white matter injury,
which was associated with hypoglycaemia and mutations in the
MTHFR gene resulting in elevated levels of plasma homocysteine
(Harteman et al., 2013a).
Encephalopathy can also result from perinatal/neonatal stroke.
For cerebral venous sinus (sinovenous) thrombosis dehydration is
added to the risk factors for neonatal stroke (Nwosu et al., 2008),
which include maternal risk factors such as infertility, primiparity,
maternal fever, meconium-stained amniotic ﬂuid, chorioamnionitis,
pre-eclampsia and intrauterine growth retardation. ComplicatedClinical Sciences, Sahlgrenska
6 50 Göteborg, Sweden.
ect.com).
. This is an open access article underdeliveries, both instrumental and emergency caesarean section, low
Apgar scores and hypoglycaemia are more frequently observed in in-
fants with neonatal stroke. Prothrombotic factors are more often ob-
served. Congenital heart disease carries also a higher risk of neonatal
stroke (van der Aa et al., 2014).
Seizures are common during neonatal encephalopathy, but may
also be due to other causes. They are commonly seen after neonatal
stroke, and may be the only clinical manifestation of this condition.
The incidence of seizures in the newborn period can only be properly
estimated with (continuous) EEG monitoring (Murray et al., 2008),
but the aetiology of seizures in (near) term infants using extensive
imaging, metabolic and genetic examinations has been studied recently
(Weeke et al., 2015). The most common aetiologies identiﬁed were
hypoxic–ischaemic encephalopathy (46%), intracranial haemorrhage
(12.2%), perinatal arterial ischaemic stroke (10.6%), cerebral sinovenous
thrombosis (2.9%), metabolic disorders including hypoglycaemia (9%),
central nervous system infection (7.1%), cerebral dysgenesis (2.9%),
and genetic disorders, predominantly benign familial neonatal seizures
(2.1%).
1.1. Pathophysiology of hypoxic–ischaemic (HI) brain injury
1.1.1. Phases of brain injury
The development of brain injury can be divided into different stages
(Fleiss and Gressens, 2012). Cerebral HI, of sufﬁcient severity to deplete
tissue energy reserves (primary phase), is often followed by near-the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mitochondrial respiration (Gilland et al., 1998) and high-energy phos-
phates (Penrice et al., 1997) after reperfusion and reoxygenation (latent
phase). Thereafter, a secondary phase occurs encompassing a decrease
in high-energy phosphates accompanied by cell demise often referred
to as secondary brain injury or secondary energy failure (Azzopardi
et al., 1989; Blumberg et al., 1997; Lorek et al., 1994).Several interven-
tions have been shown to attenuate secondary brain injury in experi-
mental models (Hagberg et al., 2014, 2015) and hypothermia has
proven effective also in the clinical setting (Azzopardi et al., 2014).
Less is known about mechanisms of long-term cell injury and repair
(tertiary phase) (Fleiss and Gressens, 2012), and so far treatment strat-
egies have focused on the latent phase. However, recent ﬁndings from
experimental studies indicate that the therapeutic window could be
extended beyond the secondary phase, and interventions targeting
late stages of inﬂammation or post-lesion repair may be a possibility
(see below).
1.1.2. Mechanisms of secondary brain injury
The speciﬁc mechanisms of secondary damage are only partly
understood, but excitotoxicity, mitochondrial impairment, intracellular
regulation of Ca2+, oxygen and nitrosative stress, deﬁciency of trophic
factors and inﬂammation are all implicated in the process (Hagberg
et al., 2014, 2015; Thornton et al., 2012). Furthermore, both accidental
and regulated (e.g. apoptosis, necroptosis) cell death appears critical
in the execution phase of cellular demise (Thornton and Hagberg,
2015; Johnston, 2005).
1.1.2.1. Excitotoxicity. Glutamate and aspartate are believed to be the
main excitatory amino acids (EAAs) in the brain (Johnston, 2005).
Besides their excitatory actions they are also known to exert toxic
effects (excitotoxicity) on neurons (Johnston, 2005) and oligodendrog-
lial precursors (OPCs) (Follett et al., 2004; Salter and Fern, 2005) in the
CNS. Both N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors are
expressed on neurons and oligodendroglial precursors (preferentially
on somata) in vulnerable areas of grey and white matter in the imma-
ture brain and NMDA receptors are expressed on microglia (Kaindl
et al., 2012; Tahraoui et al., 2001). There is evidence for a role of EAAs
in HI brain injury. Extracellular concentrations of EAAs, and to some
extent glycine, increase extracellularly during neonatal HI in mixed
grey and white matter of foetal sheep (Hagberg et al., 1987) and is
followed by a secondary increase during reﬂow (Thoresen et al.,
1997). EAAs also increasemarkedly in the CSF of newbornswith neona-
tal encephalopathy and the levels are associated with the degree of
encephalopathy and short-term outcome (Hagberg et al., 1993).
Blocking NMDA receptors before or after HI in experimental models
reduces subsequent neuronal damage (Hagberg et al., 1994)(Table 1)
and during in vitro ischaemia, NMDA receptor activation results in
Ca2+-dependent injury of oligodendroglial processes (Salter and Fern,
2005). AMPA blockade reduces grey and white matter damage when
given after HI or an excitotoxic insult (Follett et al., 2004; Hagberg
et al., 1994; Sfaello et al., 2005) (Table 1).
Overﬂowof extracellular glutamate activates both extrasynaptic and
intrasynaptic NMDA receptors (Fig. 1). The extrasynaptic component
probably predominates under HI conditions, leading to intracellular
accumulation of Ca2+ and substantial production of nitric oxide (NO),
both of which exert stress on mitochondria (Hagberg et al., 2014;
Hardingham and Bading, 2010). The mechanism underlying toxic
effects of extrasynaptic NMDA receptors on mitochondria is unknown,
but NO synthase, mitogen-activated protein kinases (particularly c-jun
N-terminal kinases), and calpains probably play a part (Blomgren et al.,
2001; Ferriero et al., 1996; Hardingham and Bading, 2010; Nijboer
et al., 2013; Pirianov et al., 2007). Intrasynaptic NMDA receptors
can alsomediate toxic effects (Wroge et al., 2012) but paradoxically inhi-
bition of synaptic NMDA receptors can also deprive the cell of anendogenous salvage pathway and trigger widespread apoptotic cell
death in the immature brain (Ikonomidou et al., 1999). Possibly this
adverse effect can be circumvented through selective blocking of
extrasynaptic NMDA receptors. For example, inhibitors of extrasynaptic
NMDA receptors that act on postsynaptic density protein 95, DAPK1, or
NMDA receptor 2B have been suggested as promising candidates (Tu
et al., 2010; Cook et al., 2012a, 2012b; Nair et al., 2013).
1.1.2.2. Mitochondrial impairment and Ca2+ regulation. During HI,
electron ﬂow through the electron transport chain slows down due to
lack of oxygen, the H+ gradient across the inner membrane decreases
and ATP production drops (Fig. 1). Under such conditions combined
with high cytosolic concentrations of Ca2+ and NO (due to activation
of NMDA receptors and opening of voltage-dependent Ca2+ channels)
the intramitochondrial Ca2+ increases (Puka-Sundvall et al., 2000).
The accumulation of Ca2+within themitochondrialmatrix activatesmi-
tochondrial phosphatases leading to hyperactivation of cytochrome c
oxidase and cytochrome c and pathological hyperpolarisation of themi-
tochondrial membrane potential during the early recovery phase after
the insult (Sanderson et al., 2013; Starkov and Fiskum, 2003).
Mitochondrial inner membrane hyperpolarisation, in turn, triggers
excessive production of reactive oxygen species (ROS) by complexes 1
and 3 (Piantadosi and Zhang, 1996; Sanderson et al., 2013; Starkov
and Fiskum, 2003) which in combination with an increase of NO
(Ferriero et al., 1996) result in suppression of mitochondrial respiration
during the early secondary phase of brain injury after HI (Gilland et al.,
1998; Starkov and Fiskum, 2003). Furthermore, ROS oxidise cardiolipin,
which in turn releases cytochrome c from the inner mitochondrial
membrane. ROS have also been proposed to oxidise Optic Atrophy 1,
leading to opening of the proximal part of the cristae thereby allowing
diffusion of cytochrome c into the intermembrane space (Ramonet
et al., 2013). Apoptosis-inducing factor (AIF) is also believed to be
attached to the inner mitochondrial membrane under physiological
conditions. Apoptosis-inducing factor can also translocate to the
intermembrane space in response to oxidative stress, activation of
poly(ADP-ribose) polymerase (PARP)1, and activation of proteases
(Modjtahedi et al., 2006). This translocation is a prerequisite for the sub-
sequent transfer of AIF to the cytosol and nucleus after mitochondrial
permeabilisation (Modjtahedi et al., 2006).
1.1.2.3. Mitochondrial permeabilisation and apoptotic cell death. At a
certain threshold of mitochondrial perturbation the organelle un-
dergoes outer membrane permeabilisation and apoptotic cell death is
executed. Proapoptotic proteins (cytochrome c and AIF) are released
frommitochondria, the apoptosome forms, and downstreamexecution-
er caspases (particularly caspase-3) are activated after HI (Cheng et al.,
1998; Galluzzi et al., 2009; Northington et al., 2011a) resulting in DNA
fragmentation and cell death. Pathways dependent on AIF (Zhu et al.,
2007) and caspases (Hu et al., 2000) seem to bemore strongly activated
in the immature brain than in the adult brain (Hu et al., 2000; Zhu et al.,
2005), and mitochondrial permeabilisation seems to mark the point of
no return in HI injury of the immature brain. Such a concept is also
supported by studies showing that apoptoticmorphologies are predom-
inant phenotypes after brain injury in the immature brain (Edwards and
Mehmet, 1996) and that treatment with hypothermia reduces apopto-
tic (rather than necrotic) cell death (Edwards et al., 1995).
The molecular mechanism of mitochondrial permeabilisation after
HI is still incompletely understood. In the adult brain, opening of a
cyclophilin D (Ppid) dependent permeability transition pore is critical
for development of ischaemic injury (Schinzel et al., 2005), whereas
Ppid gene deﬁciency has the opposite effect in immature models of HI
(Wang et al., 2009). Instead mitochondrial permeabilisation in the
immature CNS after HI depends on BAX–BAK-dependent pore forma-
tion. Hence, BAX-inhibitory peptides (Wang et al., 2009, 2010) and
BAX gene deﬁciency (Gibson et al., 2001) substantially protect the
immature brain (Table 1). Several proapoptotic and antiapoptotic
Table 1
Examples of neuroprotective treatment in animal models of hypoxia–ischemia.
Experimental model Treatment Findings
Anti-apoptotic/mitoprotective agents
Hypoxia–ischaemia in 7 day old rats
(Cheng et al., 1998)
Boc-aspartyl(OMe)-ﬂuoro-methylketone (broad spectrum
caspase inhibitor) given icv (100 nmol/pup) 3 h after insult
Decrease of caspase activity and lesion volumes in cortex,
hippocampus and striatum; attenuation of neuronal loss in
hippocampus.
Hypoxia–ischaemia in 9 day old mice
(Wang et al., 2010)
BAX-inhibiting peptide (BIP; 25 μg/pup) vs. a BIP negative
control was given icv prior to insult
BIP reduced BAX translocation to mitochondria, cytochrome C
release and caspase-3 activation; BIP attenuated infarction and
white matter injury assessed at 5 days and improved memory
and sensorimotor functions 7 weeks following insult.
Hypoxia–ischaemia in 7 day old rats
(Nijboer et al., 2011)
Piﬁthrin-μ (PFT-μ) (inhibitor of p53 association with
mitochondria) (2–8 mg/kg ip) given 0-21 h after HI.
PFT-μ(8 mg/kg) reduced mitochondrial permeabilisation,
caspase activation and tissue loss evaluated both at 2 days and
10 weeks after HI. Improvement of cognitive and sensorimotor
functions at 6–10 weeks. PFT-μwas effective if given ≤6 h after
insult.
Ibotenate in 5 day old mice; hypoxia–ischaemia
in 9 day old mice, focal ischaemia in 7 day old
rats (Chauvier et al., 2011)
TRP601 (caspase-2 inhibitor) given 0.1–1 mg/kg ip at
different time points after the insult.
TRP601 reaches the CNS, inhibits caspase-2/−3 and
mitochondrial cytochrome C release. Reduction of brain injury
in all three models with a therapeutic window of 6 h after HI;
TRP601 does not affect physiological apoptosis or CNS
development and has a favourable safety proﬁle in rodents and
canine neonates.
Immuno-modulatory and anti-oxidative agents
Hypoxia–ischaemia in 7 day old rats
(Arvin et al., 2002)
Minocycline (tetracycline derivative having
anti-inﬂammatory action) 22.5 or 45 mg/kg given ip before
or after HI.
Tissue area loss was markedly reduced in striatum, cortex and
hippocampus at 1 week after HI if drug was given before or
directly after HI; minocycline attenuated apoptotic and necrotic
cell death.
Umbilical cord occlusion, foetal sheep at 91–93
days of gestation (Welin et al., 2007)
Melatonin (20 mg/kg/h) given to the foetus iv starting
immediately after cord occlusion and for 6 h vs. vehicle.
The production of 8-isoprostanes, activated microglia cells and
TUNEL-positive cells following insult were attenuated in
melatonin treated foetuses. There was no difference in the
overall neuropathology score between groups.
Hypoxia–ischaemia in newborn piglets
(Robertson et al., 2013)
Hypothermia (33.5 °C 2–26 h after HI) vs. hypothermia +
melatonin (5 mg/kg/h) iv over 6 h
Melatonin add-on therapy increased the levels of whole brain
(31)P magnetic resonance spectroscopy nucleotide
triphosphate/phosphate pool; decreased TUNEL in thalamus,
internal capsule, putamen and caudate, caspase-3 in thalamus
and activated (CD86+) microglia.
Hypoxia–ischaemia in 7 day old rats
(Jin et al., 2007, Jin et al., 2009)
Cromolyn (inhibits mast cell degranulation)(50 mg/kg) was
given sc 30 min before, immediately, 1 h and 24 h after HI or
only immediately, 1 h and 24 h after HI.
Cromolyn reduced the number of mast cells, degranulated mast
cells and brain injury (assessed with ﬂuoro-jade B at 48 h
post-HI and neuronal loss and brain atrophy at 4 weeks) in all
brain regions. The number of astroglia and
microglial/macrophage CD45+ cells was attenuated.
Combined LPS + hypoxia–ischaemia in mice
(Bolouri et al., 2014)
1018 (innate defence regulatory peptide) was given 8
mg/kg, ip 3 h following LPS + HI.
The 1018 peptide modulated the LPS-evoked
cytokine/chemokine response to LPS in mouse microglial
cultures; 1018 reduced white and grey matter injury in vivo
and gene expression analysis showed reduction of
pro-inﬂammatory and cell death related genes.
Hypoxia–reperfusion in newborn piglets
(Liu et al., 2010)
N-acetylcysteine (150 mg/kg bolus and 20 mg/kg/h iv) for
24 h
N-acetylcysteine improved oxygen delivery and attenuated the
increase in cortical caspase-3 activity and lipid hydroperoxide
concentrations up to 48 h post-hypoxia. Reduced and oxidised
glutathione was not affected by drug treatment.
LPS + hypoxia–ischaemia in 8-day old rats
(Wang et al., 2007)
N-acetylcysteine (200 mg/kg ip) prior + directly after HI or
0 h and 24 h after HI.
N-acetylcysteine (pre + post or only post HI) reduced tissue
volume loss and neuropathology score in cerebral cortex,
hippocampus and thalamus. Isoprostane activation,
nitrotyrosine formation, caspase-1 and -3, calpain activation
were attenuated and the drug increased levels of the
anti-oxidants glutathione and thioredoxin.
Hypoxia–ischaemia in 7 day old rats
(Hagberg et al., 1996; Hu et al., 2005)
IL-1ra (IL-1 receptor antagonist) was given either 3.3 μg/rat
icv prior to HI or 2 μg/rat icv 2 h after HI.
IL-1ra reduced brain injury (assessed as hemispheric weight
deﬁcit 2 weeks after HI), DNA fragmentation and activation of
caspase-3 (in cerebral cortex and hippocampus).
Hypoxia–ischaemia in 7 day old rats
(Balduini et al., 2001; Li et al., 2010)
Simvastatin (cholesterol lowering drug) was given
prophylactically (20 mg/kg sc daily post-natal days 1–7)
prior to HI
Attenuation of volume loss in cerebral cortex, hippocampus
and whole hemisphere 10 weeks after HI. Simvastatin
attenuated behavioural deﬁcits, improved myelination
(myelin-basic protein staining) inhibited
microglial/macrophage activation (OX-42 positive cells) and
reduced the numbers of pyknotic cells.
Trophic action, enhancement of neurogenesis/myelogenesis
Hypoxia–ischaemia in 7 day old rats
(Almli et al., 2000; Han et al., 2000)
Brain-derived neurotrophic factor (BDNF) (10 μg/pup) was
administered icv prior to HI
BDNF attenuated memory and spatial memory impairments
assessed 2–3 weeks after the insult and reduced injury in
cortex, hippocampus, and striatum at 4 weeks; BDNF
attenuated markedly caspase-3 activation after the insult.
Bilateral carotid artery occlusion in near term
(121–128 days of gestation) foetal sheep
(Cao et al., 2003)
Insulin-like growth factor-1 (IGF-1) was given icv 90 min
either a single dose (3 or 30 μg), or 3 μg followed by 3 μg
over 24 h
3 μg (but not 30 μg) of IGF-1 increased myelination
(myelin basic protein + proteolipid protein mRNA) and
number of oligodendroglial precursors at 4 days after
ischemia. IGF-1 attenuated caspase-3 activation and
increased proliferation. IGF-1 over 24 h did not provide
additional beneﬁt.
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Table 1 (continued)
Experimental model Treatment Findings
Focal ischaemia (transient middle cerebral
artery occlusion) in 7 day old rats
(Gonzalez et al., 2013)
Erythropoietin (EPO) (1000 U/kg) was given icv at
reperfusion, 24 h, and 7 days later
Multiple doses of EPO shifted cell fate from astroglia
proliferation towards neurogenesis and oligodendrogliosis at 3
and 14 days in striatum.
Focal ischaemia (transient middle cerebral
artery occlusion) in 10 day old rats
(Gonzalez et al., 2007)
EPO(5 units/g) was injected ip directly upon reperfusion EPO moderately prevented hemispheric volume loss at 6 weeks
after ischaemia. EPO increased the percentage of newly
generated neurons while decreasing newly generated
astrocytes following brain injury.
Umbilical cord occlusion (15–18 min) in term
(173 days of gestation) non-human primates
(Macaca nemestrina (pigtailed macaques)
(Traudt et al., 2013)
EPO(1000 U/kg/day i.v. 30 min, 24 h, 48 h, and 7 days after
asphyxia) + hypothermia (HT) (33.5 °C for 72 h after
resuscitation) vs. only hypothermia or saline treatment
The animals were followed up for 9 months. Death or
moderate-severe cerebral palsy occurred in 44% of HT and in 0%
of HT + EPO treated animals. EPO improvement of motor and
cognitive responses, cerebellar growth, and MRI measures.
(Diffusion tensor imaging showed improved mode of
anisotropy, fractional anisotropy, relative anisotropy, and
volume ratio) as compared to saline-treated infants.
Anti-excitotoxic compounds
Hypoxia–ischaemia in 7 day old rats
(Hagberg et al., 1994; McDonald et al., 1987)
MK-801 (Dizocilpine) (NMDA-receptor antagonist) was
given ip (0.3, 0.5, 0.75 mg and 1 mg/kg) vs. vehicle after HI
MK-801 (0.3 and 0.5 mg/kg) given after HI reduced brain injury
(assessed as hemispheric weight deﬁcit vs. contralateral);
MK-801 (0.5 mg/g) reduced cortical infarct volume. A dose of 1
mg/kg given before or during HI (but not after HI) reduced
hemispheric injury assessed 5 days after HI.
Bilateral carotid artery occlusion in near term
(123–137 days of gestation) foetal sheep
(Tan et al., 1992)
MK-801 (Dizocilpine)(0.3 mg/kg ip bolus) was given at 6 h
after the insult followed by continuous infusion of 1 mg/kg
over the next 36 h
The intense epileptiform activity seen in the control group
during recovery was completely suppressed in the
MK-801-treated group. The onset of secondary cortical edema
was delayed and neuronal damage was reduced, particularly in
the lateral cortex and hippocampus 3 days after insult.
Hypoxia–ischaemia in 7 day old rats
(Andine et al., 1988)
Kynurenic acid (non-speciﬁc antagonist of excitatory amino
acid receptors) (300 mg/kg) immediately after HI
Kynurenic acid reduced brain injury (assessed as hemispheric
weight deﬁcit vs. contralateral) 2 weeks after HI.
Hypoxiaischaemia in 7 day old rats
(Hagberg et al., 1994)
NBQX (AMPA-receptor antagonist) (15 + 15 or 20 + 20
mg/kg) ip directly and 1 h after HI
NBQX (20 + 20 mg/kg) attenuated hemispheric volume loss
after HI, improved morphology score and reduced the infarct
volume. The lower dose did not affect outcome.
Hypoxia–ischaemia in 7 day old rats
(Follett et al., 2000)
NBQX (AMPA-receptor antagonist) (20 mg/kg) ip starting
directly after HI and thereafter repeated doses every 12 h
for 48 h
NBQX improved myelination 4 days after HI (assessed with
myelin basic protein immunoreactivity) and provided a
signiﬁcant preservation of O1 positive oligodendroglial
precursors.
Hypoxia–ischaemia (transient occlusion of
carotid arteries and hypotension) in newborn
piglets (Schubert et al., 2005)
Topiramate was given as a loading dose 50 mg/kg 1 h after
insult and maintenance dose 20 mg/kg/day until
termination of the experiment after 72 h
Topiramate treated animals exhibited a markedly reduced
amount of neuronal damage in frontal, temporoparietal and
occipital cortex, striatum and hippocampus compared with
vehicle-treated 3 days after HI. There was increased numbers of
TUNEL positive cells in subventricular zone and frontal white
matter in topiramate treated piglets.
Hypoxia–ischaemia in 7 day old rats
(Noh et al., 2006)
Topiramate (20, 50, 100 mg/kg/dose ip) before and after HI
or only after (directly +2 h post HI); also peroral treatment
(50 mg/kg/dose) pre + post HI was given
Topiramate given iv or perorally reduced brain damage in
cortex, striatum and hippocampus 5 days after HI and
attenuated cognitive impairments. Treatment was also effective
if given 2 h after HI.
Hypoxia–ischaemia in 7 day old rats
(Ma et al., 2005)
Xenon (20–70%) was either added during HI or 2 to 24 h
after the insult for 90 min alone or in combination with HT
(30–35 °C) for different durations
A combination of xenon and HT administered 4 h after HI injury
in neonatal rats provided synergistic neuroprotection assessed
by morphology, hemispheric weight, and by functional
neurological (motor and balance) assessments up to 30 days
after the injury.
Global hypoxia–ischaemia in newborn pigs
(Chakkarapani et al., 2010)
Xenon (50%) for 18 h after HI in combination with
normothermia or HT (33.5 °C) for 12 h or 18 h compared
with no treatment or HT for 12 h or 18 h without Xenon
Combining xenon with HT provided added neuroprotection,
e.g. xenon and 24 h HT offered marked histological
neuroprotection in thalamus, brainstem, white matter, basal
ganglia, cortical grey matter, cerebellum and hippocampus
assessed 3 days after HI. Neurologic functional scores improved
in the xenon + HT group.
Abbreviations: EPO – erythropoietin; HI — hypoxia–ischaemia; HT — hypothermia; icv — intracerbroventricularly; ip — intraperitoneally; iv— intravenously; LPS— lipopolysaccharide;
NBQX — 6-nitro-7-sulfamoylbenzo(f)quinoxaline-2,3-dione; sc— subcutaneously.
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BAX–BAK dependent mitochondrial permeabilisation (Ness et al.,
2006). Additionally, interaction of the tumour suppressor p53 and
xcaspase-2 with BCL2 members at the outer mitochondrial membrane
contributes to mitochondrial permeabilisation (Carlsson et al., 2011;
Nijboer et al., 2011). The above mentioned interventions targeting
BAX–BAK-dependent mitochondrial permeabilisation directly or indi-
rectly, are neuroprotective (Table 1), suggesting a central role for
mitochondria in directing apoptotic cell death in the developing brain.
1.1.2.4. Necrotic/necroptotic cell death. Another major form of cell
death is necrosis, which initially was considered to be accidental or
uncontrolled, characterised by cellular swelling andmembrane rupture.
However, it is now clear that at least some forms of necrosis result froma regulated series of events referred to as regulated or programmed ne-
crosis which occurs in an environment that is either dramatically
depleted of ATP or in which caspases are inhibited (Galluzzi et al.,
2011; Vanden Berghe et al., 2014). One form of regulated necrosis,
“necroptosis”, depends on activation of receptor-interacting kinase
(RIP)3, mixed lineage kinase domain-like (MLKL) and sometimes
RIP1. In a neonatal mouse model of HI, administration of necrostatin-1
(RIP1 inhibitor) attenuated progression of injury and appeared to shift
cell death towards apoptosis (Northington et al., 2011b). Necrostatin-
1 also decreased the accumulation of oxidants, prevented the decline
in mitochondrial complex I activity and improved ATP levels after HI
(Chavez-Valdez et al., 2012), supporting the concept that execution of
necroptosis in the immature brain depends on mitochondria at least
partly (Thornton and Hagberg, 2015).
Fig. 1. Role of mitochondria in hypoxic–ischaemic brain injury. During early reperfusion, extracellular glutamate activates NMDA receptors leading to intracellular accumulation of Ca2+
and nitric oxide (NO). NO and mitochondrial Ca2+ accumulation (Ca2+ dysregulation) elicit production of reactive oxygen species (superoxide, O2.-) which induces respiratory suppres-
sion, and contributes to translocation of cytochrome c (CytC) and apoptosis-inducing factor (AIF) from the innermitochondrialmembrane/cristae to the intermembrane space. An increase
of pro-apoptotic compared with anti-apoptotic BCL2 family proteins, activation of caspase-2, and interaction of p53 with the outer mitochondrial membrane leads to mitochondrial
permeabilisation. The subsequent release of CytC triggers a cascade including assembly of the apoptosome and activation of executional caspases and, leading to degradation of DNA
and essential proteins, and resulting in cell death. AIF binds to cyclophilinA (CyA) and the complex translocates to the nucleus and induces chromatinolysis. PSD-95=postsynaptic density
protein 95. nNOS = neuronal NO synthase. CAD = caspase-activated DNase. ICAD= inhibitor of CAD. APAF1 = apoptic peptidase activating factor 1.
106 H. Hagberg et al. / Neurobiology of Disease 92 (2016) 102–1121.1.2.5. Inﬂammation. HI or stroke induces an inﬂammatory reaction in
the immature brain (Hagberg et al., 2015; Derugin et al., 2000). Cells
belonging to the innate or adaptive immune system are activated in-
cluding microglia/macrophages (McRae et al., 1995; Tahraoui et al.,
2001), polymorphonuclear cells (Bona et al., 1999; Palmer et al.,
2004), lymphocytes (Bona et al., 1999; Winerdal et al., 2012), NK-cells
(Bona et al., 1999; Winerdal et al., 2012) and mast cells (Patkai et al.,
2001; Jin et al., 2009). The accumulation of cells is accompanied by
altered expression of innate immune receptors (including Toll-like re-
ceptors (TLRs) and Nodd-like receptors (NLRs) cytokines, chemokines,
ROS, excitatory amino acid agonists, and death receptor agonists includ-
ing TNF, FasL, RANKL, TRAIL and TWEAK which could contribute to cell
death (Hagberg et al., 1996; Hedtjarn et al., 2002, 2004; Ivacko et al.,
1997; Kichev et al., 2014; Mallard et al., 2009; Silverstein et al., 1997).
In parallel to these alterations, the blood–brain-barrier undergoes
transient opening at 6–24 h after HI (Ek et al., 2015). The initial inﬂam-
matory response is thought to depend on activation of innate immune
receptors. TLRs are induced during recovery from neonatal HI, and
knocking out Tlr2 in mice provides neuroprotection (Stridh et al.,
2011). Indirect evidence suggests that the inﬂammasome and NOD-
like receptors also are involved as IL-1 production is increased after HI
(Hagberg et al., 1996) and injury is attenuated by the IL-1 receptor
antagonist IL-1RA (Hagberg et al., 1996) or by caspase-1 or IL-18 gene
deﬁciency (Hedtjarn et al., 2002; Liu et al., 1999). There is further sup-
port that the early proinﬂammatory phase aggravates injury after HI,
as inhibition of platelet-activating factor (Liu et al., 1996) and the com-
plement C1q reduce HI injury (Ten et al., 2005). The inﬂammatory reac-
tion is highly dependent on context and time. For example, the
microglial/macrophage responses exert beneﬁcial or detrimental effects
depending on the phenotype. Microglia are likely to assume distinct
functional phenotypes after HI in analogy with the M1, M2a and M2b
phenotypes suggested in other models (Chhor et al., 2013; Colton and
Wilcock, 2010). There are multiple neuroprotective interventions thathave been proven effective in experimental and clinical studies that
mainly or partly modify the immunoinﬂammatory response (Table 1).
1.1.3. Tertiary phase of brain injury
As mentioned previously, experimental and human data strongly
support the fact that hypothermia is neuroprotective in term infants if in-
troduced within the ﬁrst 6 h (see below) after birth. However, the thera-
peutic windowmay bemuch longer than that. Some studies suggest that
it may be possible to intervene during the delayed inﬂammatory phase
and improve post-lesional plasticity (Fleiss and Gressens, 2012). An in-
triguing clinical study has recently shown that EPO,when given on an av-
erage of 24 h after birth, had very signiﬁcant neuroprotective effects on
human term infantswith neonatal encephalopathy (Zhu et al., 2009). Ge-
netic upregulation of the complement factor C3a 6 h–7 days after HI sig-
niﬁcantly improved neurogenesis, memory functions and reduced brain
injury in 9-day-oldmice (Jarlestedt et al., 2013).Most impressively, intra-
cerebral or intranasal administration ofmesenchymal stemcells as late as
3–10 days following HI reduces lesion size and substantially improves
memory and sensory-motor functions after HI in newborn rodents
(Donega et al., 2013; van Velthoven et al., 2010).
1.1.4. Diagnosis of brain injury
Many tests are performed to diagnose the extent and severity of
perinatal brain damage (Table 2).
1.1.5. Clinical assessment
1.1.5.1. Apgar score. The Apgar score has been used as one of the ﬁrst
tests used to assess the severity of perinatal asphyxia. At present the
Apgar score is no longer considered to be amarker of perinatal asphyxia
and encephalopathy, although the score still predicts outcomes at a
population level and the prognosis of term neonates with a very low
Apgar score at 5 or 10 min after birth remains poor (Bonifacio et al.,
2015; Casey et al., 2001; Laptook et al., 2009; Sarkar et al., 2010).
Table 2
Techniques used for assessment of brain injury after perinatal hypoxia–ischaemiaa.
Advantages Disadvantages
Clinical methods
Apgar score Used worldwide, cheap,
easily applicable, high
prediction of mortality in
case of low score at 5 min
(Bonifacio et al., 2015;
Casey et al., 2001;
Laptook et al., 2009;
Sarkar et al., 2010)
Not speciﬁc for
hypoxia–ischaemia;
infection, sedative drugs,
congenital abnormalities
may lower Apgar scores
Clinical examination
Sarnat score (Sarnat and
Sarnat, 1976)
Widely accepted, used as
entry criteria in clinical
trials (Shankaran et al.,
2005)
Based on a limited
number of patients;
consists of a combination
of clinical assessment and
EEG, not speciﬁc for
hypoxia–ischaemia
Thompson score
(Thompson et al.,
1997)
Does not require
expensive technology,
easily applicable
Not speciﬁc for
hypoxia–ischaemia,
not widely accepted
Biochemical methods
(Umbilical cord) blood
gas values (Bonifacio
et al., 2015; Wayock
et al., 2014)
Excellent information on
hypoxia-induced
metabolic acidosis, widely
accepted
Need to be performed
rapidly after birth
No direct relation with
severity or extent of brain
injury
Biomarkers(S100b, NSE)
(Massaro et al., 2012;
Serpero et al., 2013;
Tonni et al., 2014)
Easily applicable No direct relation with
localization of brain injury
Electrophysiological methods
Evoked potentials (Eken
et al., 1995;
van Laerhoven et al.,
2013)
Good predictive value after
asphyxia
Not easily applicable,
technically difﬁcult,
not speciﬁc for
hypoxia–ischaemia
Amplitude-integrated
EEG (Thoresen et al.,
2010;
Toet et al., 1999; van
Laerhoven et al.,
2013)
Continuous information of
presence of seizures and
background activity;
excellent predictive value
after perinatal asphyxia
Requires training of
neonatal staff
Not speciﬁc for
hypoxia–ischaemia
Near-infrared spectroscopy
NIRS (Lemmers et al.,
2013)
Good predictive value after
asphyxia
Not easily applicable; only
trend monitor;
limited experience
Neuroimaging
Cranial ultrasound (Eken
et al., 1994)
Bedside technique,
excellent tool
for diagnosis of major
haemorrhage or changes
in basal ganglia/thalamus
after asphyxia; can be
performed repeatedly
Ischaemic changes can be
seen after 2 days; requires
training of
neonatal/radiology staff
MRI (Alderliesten et al.,
2011; Rutherford
et al., 2010)
Excellent predictive value
after asphyxia; essential to
detect other causes of
neonatal encephalopathy
(ischaemic stroke,
sinovenous thrombosis,
infections, metabolic
causes, congenital
malformations)
Not easily applicable;
requires extensive
training of
neonatal/radiology staff;
optimal timing not yet
established (in particular
after therapeutic
hypothermia); impossible
in most severe cases due
to clinical limitations
Proton MR
spectroscopyb
(Alderliesten et al.,
2011;
Thayyil et al., 2010)
Excellent predictive value
after asphyxia
Not easily applicable;
requires extensive
training of
neonatal/radiology staff;
impossible in most severe
cases due to clinical
limitations
a Most techniques were studied prior to the era of therapeutic hypothermia; hypo-
thermia may change the predictive value of these techniques (Sabir and Cowan, 2015).
b Not an imaging technique, but data are obtained during the same session as MRI.
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widely to assess the severity of neonatal encephalopathy. The most
commonly used is the Sarnat score (Sarnat and Sarnat, 1976).This
score combines information of clinical examinations and EEG and
grades encephalopathy as mild (grade I), moderate (grade II) or
severe (grade III). Outcome of infants with mild encephalopathy is uni-
formly good, whereas 25% of infants withmoderate and almost 100% of
infants with severe encephalopathy die or show severe impairments.
Alternatives which are used nowadays are the Thompson score system
(Thompson et al., 1997), which uses more clinical items than the Sarnat
score, and does not need electrophysiological assessment. These scores
have little value in diagnosing the cause of the encephalopathy.
1.1.6. Biochemical assessment
1.1.6.1. Blood gas values. Blood gas values have been reported as better
indices of perinatal asphyxia than the Apgar score. Indeed, a relation
between pH values and the occurrence of severe encephalopathy has
been demonstrated (Goodwin et al., 1992; Lavrijsen et al., 2005). Never-
theless, many patients with a pH value of the umbilical artery below 7.0
do not show any signs of encephalopathy. Blood gas values remain
associated with outcome in the era of therapeutic hypothermia
(Bonifacio et al., 2015; Wayock et al., 2014).
1.1.6.2. Biomarkers. Biochemical biomarkers have been examined during
recent decades, but none of the biomarkers tested were able to predict
the presence of brain injury (Serpero et al., 2013), although they
might be useful in speciﬁc diseases (Tonni et al., 2014).
1.1.7. Electrophysiology
1.1.7.1. Evoked potentials and amplitude-integrated EEG. Evoked
potentials have some value in determining the severity of a hypoxic–
ischaemic insult in an encephalopathic term neonate (Eken et al.,
1995; van Laerhoven et al., 2013). They are indicative of the severity
of brain injury, and are predictive of outcome, but are less commonly
used since the introduction of aEEG.
EEG, in particular amplitude-integrated continuous EEG (aEEG) is
commonly used in encephalopathic infants, in particular in Europe
(Boylan et al., 2013), and can help detect seizures. aEEG abnormalities
(seizures and a suppressed background pattern) have high predictive
values towards an adverse outcome after perinatal asphyxia (Toet
et al., 1999; van Laerhoven et al., 2013), both in normothermic infants
as well as during therapeutic hypothermia (Thoresen et al., 2010).
1.1.8. Near-infrared spectroscopy
Near-infrared spectroscopy (NIRS) is applied in term neonates
with perinatal asphyxia to measure brain oxygen saturation. In severe
encephalopathy following perinatal asphyxia very high oxygen
saturation levels have been encountered, coinciding with low aEEG
background patterns. This suggests lack of oxygen consumption in
these affected infants, and helps predict a poor outcome (Lemmers
et al., 2013).
1.1.9. Neuroimaging
1.1.9.1. Cranial ultrasound. Cranial ultrasound is a useful technique to
detect major abnormalities including large intraventricular, subdural,
or cerebellar haemorrhage, ischaemic infarctions, and calciﬁcations
(Steggerda et al., 2009). In term neonates major changes to the basal
ganglia and thalamus can sometimes be identiﬁed during the ﬁrst
days after an acute hypoxic–ischaemic insult, although ultrasound
lacks sensitivity and speciﬁcity in predicting outcomes in neonatal
encephalopathy (Eken et al., 1994).
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sensitive technique to detect abnormalities in the brain, but speciﬁc
and neonatally-adapted sequences are required to obtain maximal
information. In addition to standard sequences diffusion weighted im-
aging is needed to detect cytotoxic oedema within the ﬁrst week after
the hypoxic–ischaemic insult, susceptibility weighted sequences may
be needed to detect small haemorrhages, and MR angiography and
venography are required to detect abnormalities in blood vessels.
MRI abnormalities have a high predictive value for an abnormal out-
come, also in the era of therapeutic hypothermia following perinatal
asphyxia (Alderliesten et al., 2011; Rutherford et al., 2010). MRI is also
useful to detect other acquired brain injuries such as lesions due to trau-
ma, sinovenous thrombosis and arterial infarctions.
Proton MR spectroscopy of the basal ganglia and thalamus has a
reasonably high predictive value for an abnormal neurodevelopmental
outcome (Alderliesten et al., 2011).Even with dedicated MRI systems
brain injury may be less well detected than through histology
(Alderliesten et al., 2013).
1.2. Outcome of perinatal brain damage
Outcomeofmoderate-to-severe encephalopathy following perinatal
asphyxia is still a matter of concern (Jacobs et al., 2013). Although the
introduction of therapeutic hypothermia has reduced the incidence of
poor outcome from approximately 60% to 45%, death or neuromotor
impairment is still common.
The most severe forms of perinatal brain damage will lead to
cerebral palsy. When the basal ganglia and thalamus are involved as
in kernicterus or severe, acute perinatal asphyxia the cerebral palsy
will be of the dyskinetic quadriplegia type, whereas unilateral spastic
cerebral palsy will be seen after unilateral infarcts such as middle cere-
bral artery infarct.
After white matter injury long-term cognitive and behavioural
consequences are more commonly seen (Van Kooij et al., 2010),
although the outcome is not invariably poor (Harteman et al., 2013b).
The speciﬁc pattern ofMRI changes after perinatal asphyxia and theout-
come may be dependent on several associated factors, including
hypoglycaemia, genetic factors, and placental pathology (Harteman
et al., 2013c; Martinez-Biarge et al., 2013).
Recent papers suggest that milder encephalopathy may result in
subtle changes in neurodevelopment later in life (Van Kooij et al., 2010).
1.3. Treatment of perinatal brain damage at term
The goal of neuroprotective therapy is to prevent injury progression,
salvage and protect the cells that would otherwise be injured or die, re-
pair the injured cells, and enhance neurogenesis with the long-term
goal of improving neurodevelopmental outcomes.Much has been learnt
from animal and adult studies on brain injury looking at potential treat-
ment strategies (Table 1), and allowing for potential translation into
clinical research and trials. The success of moderate hypothermia in
term hypoxic–ischaemic encephalopathy has provided proof of concept
that neural rescue by intervention after the hypoxic–ischaemic insult is
possible.
1.3.1. Hypothermia
Therapeutic hypothermia using a targeted temperature reduction
regimen in which there are sequential phases of moderate cooling,
maintenance and slow rewarming is the standard of care for neonatal
hypoxic–ischaemic injury in term infants (Azzopardi et al., 2009;
Gluckman et al., 2005; Shankaran et al., 2005; Zhou et al., 2010). Six
major clinical trials in neonates – The Cool Cap, NICHD, TOBY,
neo.nEURO.network Trial, the China Study Group, and ICE trials – all
showed either overall beneﬁt of cooling for HIE or beneﬁt within sub-
groups (Azzopardi et al., 2009; Gluckman et al., 2005; Jacobs et al.,
2011; Shankaran et al., 2005; Simbruner et al., 2010; Zhou et al.,2010). Meta-analysis showed that therapeutic hypothermia reduced
death or disability in moderate encephalopathy at 18 months with a
risk ratio of 0.62 [95% conﬁdence interval (CI) 0.50–0.77] and in severe
encephalopathy a risk ratio of 0.88 (95% CI 0.78–0.99) (Edwards et al.,
2010). With cooling, 6 out of 10 infants with moderate to severe insult
have a normal outcome at 2 years of age. The NICHD Whole Body
Cooling trial and TOBY trials show that the reduction of death and
disability noted at 18 months persist to childhood (Azzopardi et al.,
2014; Shankaran et al., 2012), although there were some differences:
in the NICHD trial the effect was through reduced death, while in
TOBY there was no difference in the death rate, rather a reduction in
impairment in survivors. Adverse events (AEs) such as arrhythmias,
bleeding, skin effects due to cooling, hypotension, persistent pulmonary
hypertension and infection were minimal in the clinical trials
(Shankaran et al., 2008), but in post-introduction surveillance sub-
cutaneous fat necrosis was noted in 1% of the cases registered with
the UK cooling register (Strohm et al., 2011).
Hypothermic neural rescue is now widely practised as standard of
care in developed countries. The American Heart Association and the
National Institute for Health and Clinical Excellence (UK) recommend
that therapeutic hypothermia be commenced as post resuscitation
care for term infantsmeeting the criteria used in published clinical trials
and the British Association of Perinatal Medicine published guidelines
for neonatal units and networks to standardise hypothermia therapy
(Adams et al., 2010; Kattwinkel et al., 2010; NICE, 2010). The economic
beneﬁt of cooling calculated from increase in economically active
survivors and reduction in costs of care of disabilities is already in excess
of £100 million (Edwards et al., 2013).
Further research into hypothermia is ongoing. Although cooling has
been shown to be beneﬁcial in high resource settings, this has not been
shown in low resource settings and a clinical trial looking at cooling in
a low resource setting is currently underway (ISRCTN89547571).
Although in the cooling trials, hypothermia was initiated at a median
age of 4 h and continued for 72 h, it is not known whether delay in
cooling or continuing hypothermia may also be beneﬁcial. A clinical
trial: Late Hypothermia for HIE (NCT00614744) is currently ongoing
where term infants between 6 and 24 h of age will be recruited and
hypothermia will be continued for 96 h.
1.3.2. Novel and experimental treatments
Although hypothermia has been successful, the rate of death or
moderate to severe disability in infants with moderate to severe HIE
after cooling is 46% (95% CI 40–53%) (Edwards et al., 2013). There is
still an urgent need for additional therapies to improve outcomes and
achieve maximal neuroprotective effect. A number of therapies are in
the preclinical phase or currently undergoing phase 2 and phase 3
clinical trials.
1.3.2.1. Erythropoeitin (EPO). EPO is a growth factor with immunomodu-
latory, vasogenic and proangiogenic effects, best known as a regulator of
red cell production (Chong et al., 2002; Wang et al., 2004; Villa et al.,
2003). There is increasing evidence that EPO has a neuroprotective
effect through both direct neuronal receptor mediated interaction and
indirect effects (Edwards et al., 2013). It has been shown in many
animal models that EPO decreases apoptosis (Digicaylioglu and
Lipton, 2001), excitotoxicity (Kellert et al., 2007), glutamate toxicity
(Kawakami et al., 2000) and inﬂammation (Sun et al., 2005). EPO has
been shown to improve cognitive outcome (Kumral et al., 2004; Sola
et al., 2005a, 2005b) with evidence of neurogenesis (Plane et al., 2004;
Wang et al., 2004) (Table 1). Delayed treatment 24 h after the insult
has also shown to be neuroprotective (Sun et al., 2005). Five clinical
trials looking at safety and efﬁcacy of EPO as a potential neuroprotective
therapy in neonates have been published: two in preterm infants and
three in term infants (Elmahdy et al., 2010; Fauchere et al., 2008; Juul
et al., 2008; Zhu et al., 2009; Wu et al., 2012), however only 2 of these
studies looked at outcome measures. In both the clinical trials, the
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intention to treat analysis.
1.3.2.2. Xenon. Xenon is an anaesthetic noble gas which is a non-
competitive antagonist of the NMDA subtype of the glutamate receptor
(Franks et al., 1998) and which also inhibits the apoptotic pathway
through Bcl-XL and Bcl-2 (Ma et al., 2007) (Table 1), inducing the
expression of HIF 1α and its downstream effectors erythropoietin and
vascular endothelial growth factor (Kilic et al., 2005). It is highly
neuroprotective in a variety of models of acute neuronal injury
(Dingley et al., 2006; Ma et al., 2003, 2006; Wilhelm et al., 2002).
There are a number of clinical trials ongoing looking at the neuroprotec-
tive effects of xenon. There is a study in adults looking at the synergistic
neuroprotection of xenon and hypothermia following cardiopulmonary
arrest (NCT00879892). The COOLXENON-2 trial is studying the effect in
term HIE infants of inhaled xenon 50% for 18 h and 72 h of cooling as
standard with normalisation of aEEG and MRI at term weeks of age as
primary outcome (NCT01545271). The TOBYXe Study is recruiting
term moderate to severe HIE neonates to 30% inhaled xenon for 24 h
starting within 12 h of birth along with therapeutic hypothermia for
72 h as standard treatment (NCT00934700); this trial has already
reported an anticonvulsant effect of xenon in encephalopathic infants
(Azzopardi et al., 2013). Results of these studies are awaited.
1.3.2.3. Topiramate (TPM). TPM is an anticonvulsant with neuroprotec-
tive properties in animal models (Costa et al., 2006; Guerrini and
Parmeggiani, 2006; Shank et al., 2000; Yang et al., 1998) (Table 1),
acting by inhibiting the glutamate receptors AMPA and kainate recep-
tors along with blockade of the sodium channels, high voltage calcium
channels and mitochondrial permeability transition pore (MPTP)
(Costa et al., 2006; Kudin et al., 2004; Zona et al., 1997). So far, no clinical
trials have been published proving the neuroprotective action of TPM
with or without hypothermia in newborns with HIE. There is a clinical
trial currently running on safety and efﬁcacy of topiramate in neonates
with hypoxic ischaemic encephalopathy treated with hypothermia
(NeoNATI) (NCT01241019) where 10 mg/kg of topiramate is being
administered orally in the ﬁrst 3 days of life with neurologic and
neuroradiologic outcome at 24 months.
1.3.2.4. Melatonin. Melatonin (N-acetyl-5-methoxytriptamine) is a
naturally occurring hormone secreted by the pineal gland which inﬂu-
ences the sleep–wake cycle (Reiter, 1991) and has neuroprotective
properties ofmelatonin probably both through theMT1 andMT2 recep-
tors (Dubocovich et al., 2010) and through direct receptor-independent
free radical scavenging actions (Tan et al., 2002).
There is strong experimental evidence of a neuroprotective effect of
melatonin (Table 1). Husson et al. showed that melatonin at lower
doses decreases white matter lesions but not cortical lesions while
antioxidants like N-acetylcysteine appears to protect both lesions
(Husson et al., 2002). In a recent study in the perinatal asphyxia piglet
model, Robertson et al. showed that the Lac/Cr and Lactate/N acetyl as-
partate were signiﬁcantly lower in the piglets who received melatonin
along with moderate hypothermia (Robertson et al., 2013). Clinical tri-
als are awaited.
1.3.2.5. Stem cell therapy. Stem cells are multipotent cells, capable of
long-term self-renewal and possess extensive proliferative capacity. A
variety of stem cell approaches are proposed for treatment of HIE and
include neural stem cells, mesenchymal stem cells, cord blood cells
and foetal grafts.
In adult animals neural stem cell (NSC) transplantation after brain
injury results in integration of the cells into the injured tissue (Hicks
et al., 2007), decreased volume loss (Hoehn et al., 2002) and improved
functional recovery (Hicks et al., 2007). In the neonatal models,
implantation of NSCs also resulted in migration to injured areas with
differentiation into neuronal cell types (Park et al., 2006a, 2006b; Satoet al., 2008). In hypoxic ischaemic rats cells transplanted 3 days after
the insult initially proliferatedwith some cells surviving for a prolonged
period (Obenaus et al., 2011). There are currently no clinical trials in
neonates using NSCs.
Mesenchymal stem cells (MSCs) have the ability to differentiate
not only into cells of mesodermal lineage but also neurons as well. In
neonatal HI, transplantation of MSCs from umbilical cord blood resulted
in functional improvement with decrease in activated microglia
(Pimentel-Coelho and Mendez-Otero, 2010), and Kaneko et al. have
also shown in rat neurons subjected to HI injury, combination of MSCs
with hypothermia signiﬁcantly improved the survival of the neurons
(Kaneko et al., 2012). As these cells are available in abundance and
ethically acceptable, there has been an interest in umbilical cord blood
cell transplantation, and there is currently a safety and feasibility
study using autologous human umbilical cord cells for neonatal enceph-
alopathy in the ﬁrst 14 days of life conducted at Duke University
(NCT00593242).
2. Conclusions
Perinatal brain damage in the term infant remains an important
clinical problem. Adverse outcome after severe term perinatal asphyxia
is still 45%. Although many aspects of the pathophysiology of hypoxic–
ischaemic brain injury have been elucidated, therapeutic hypothermia
is the only neuroprotective strategy for standard care. Further studies
are needed to evaluate the use of compounds that have been shown
effective in animal experiments.
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